Supplementary Material

Supplementary Table S1: Number of Metastatic Lymph Nodes Retrieved in ICG versus non-ICG Groups.

Study	*Mean total lymph nodes retrieved per patient* *ICG vs non-ICG (mean±SD)*	*Mean number of metastatic lymph nodes per patient* *ICG vs non-ICG (mean±SD)*	*Total metastatic lymph nodes retrieved (proportion)* *ICG vs non-ICG (%)*
Romanzi[28]	40 vs 24	N/A	N/A
Cianchi[29]	50.8 ±17.1 **vs** 40.1±23.0, P<0.03	4.0±5.4 **vs** 4.4±6.8	N/A
Tian[30]	39.19 ± 8.97 vs 35.28 ± 9.00	N/A	49/1058 (4.63%) vs 67/1129 (5.93%)
Lan[31]	35.8 vs 30	N/A	N/A
Kwon[32]	48.9 vs 35.2	5 vs 4	5/1956 (0.26%) vs 4/1408 (0.28%)
Fujimoto[33]	31.2 vs 25.6	N/A	N/A

Supplementary Table S2: Risk of Bias among included studies (MINORS rating score)

Methodological item for non-randomized studies	**Romanzi[28]**	**Cianchi[29]**	**Tian[30]**	**Lan[31]**	**Kwon[32]**	**Fujimoto[33]**
A clearly stated aim	2	2	2	2	2	2
Inclusion of consecutive patients	2	1	0	1	2	2
Prospective collection of data	2	2	0	0	2	2

Endpoints appropriate to the aim of the study	2	2	2	2	2	2
Unbiased assessment of the study endpoint	2	2	2	2	2	2
Follow-up period appropriate to the aim of the study	2	2	2	2	2	2
Loss to follow up less than 5%	2	2	2	2	2	2
Prospective calculation of the study size	0	0	0	0	0	2
Additional criteria in the case of comparative studies						
An adequate control group	2	2	2	2	2	2
Contemporary groups	0	1	1	1	0	2
Baseline equivalence of groups	1	2	1	2	2	2
Adequate statistical analyses	2	2	2	2	2	2
SCORE	**19**	**20**	**16**	**18**	**20**	**24**

[The items are scored: 0 (not reported), 1 (reported but inadequate) or 2 (reported and adequate). The global ideal score is 16 for non-comparative studies and 24 for comparative studies.]